1Cell.Ai Named Best Healthtech Startup 2026

Recognised for Innovation in Precision Oncology & Patient Impact

x

    Request a Callback

    Fill in your details and our team will get in touch with you.


    FAQ’s

    Interpreting Reports

    Understanding variants, VAFs, actionability and how clinicians read an NGS report end to end.

    All
    Clinicians
    Patients
    Cost, TAT & Logistics
    CTC Testing
    Interpreting Reports
    Liquid Biopsy & ctDNA
    NGS for Oncologists
    Tissue NGS
    Back to FAQ's
    01 How should low VAF variants be interpreted? Patients

    Low variant allele frequency (VAF) findings should be interpreted in context rather than dismissed, since a low VAF can reflect low tumor content, tumor heterogeneity, subclonal populations, or early ctDNA shedding. Confirming the variant’s read depth and quality, and correlating with the clinical picture, helps distinguish a true low-level variant from technical noise or clonal hematopoiesis.

    02 What does “ctDNA not detected” mean clinically? Clinicians

    “ctDNA not detected” means no circulating tumor DNA was found above the assay’s limit of detection, which is reassuring but not proof that cancer is absent. Some tumors shed little or no ctDNA, so the result should be interpreted alongside imaging and clinical findings rather than as a standalone all-clear.

    No results found!

    Still have questions?

    Need help understanding your report?

    Our oncology support team can help clinicians and patients navigate precision oncology insights — from sample logistics to interpreting actionable variants.

    NABL & CAP accredited lab · Pune, India · 1800 123 12355

    1Cell.Ai
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.